NRx Pharmaceuticals’ (NRXP) “Buy” Rating Reaffirmed at D. Boral Capital

D. Boral Capital restated their buy rating on shares of NRx Pharmaceuticals (NASDAQ:NRXP) in a research report sent to investors on Monday,Benzinga reports. D. Boral Capital currently has a $31.00 target price on the stock.

Other research analysts have also recently issued research reports about the stock. Ascendiant Capital Markets lifted their price objective on shares of NRx Pharmaceuticals from $44.00 to $45.00 and gave the company a “buy” rating in a report on Monday, December 2nd. HC Wainwright reaffirmed a “buy” rating and issued a $19.00 price objective on shares of NRx Pharmaceuticals in a report on Friday.

NRx Pharmaceuticals Price Performance

Shares of NRx Pharmaceuticals stock opened at $2.05 on Monday. The firm has a fifty day moving average price of $2.99 and a 200 day moving average price of $2.02. NRx Pharmaceuticals has a 1 year low of $1.10 and a 1 year high of $6.01. The stock has a market cap of $34.68 million, a PE ratio of -0.96 and a beta of 1.22.

NRx Pharmaceuticals (NASDAQ:NRXP) last issued its earnings results on Friday, March 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.10). As a group, equities analysts expect that NRx Pharmaceuticals will post -1.75 EPS for the current year.

Institutional Trading of NRx Pharmaceuticals

Several institutional investors have recently modified their holdings of NRXP. Sassicaia Capital Advisers LLC acquired a new position in NRx Pharmaceuticals during the fourth quarter worth about $33,000. Townsquare Capital LLC acquired a new position in NRx Pharmaceuticals during the third quarter worth about $25,000. Squarepoint Ops LLC acquired a new position in NRx Pharmaceuticals during the fourth quarter worth about $56,000. Millennium Management LLC acquired a new position in NRx Pharmaceuticals during the fourth quarter worth about $61,000. Finally, Anson Funds Management LP acquired a new position in NRx Pharmaceuticals during the third quarter worth about $241,000. Institutional investors and hedge funds own 4.27% of the company’s stock.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.